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ABSTRACT: Despite its occurrence as a commensal, Escherichia coli is also notorious as a pathogen. One variation 
between these commensals and pathogens is the presence of specific factors one of which are the pathogenicity islands. 
One of the most commonly occurring of these is the PAI IV536. Potentially pathogenic species have been described in non-
clinical settings. This often raises concerns on the role these environments play in transmission. This study therefore aimed 
at comparing the pathogenic ability of E. coli isolates from clinical and non-clinical sources based on the presence of the 
PAI IV536 marker. Thirty-five E. coli isolates were analyzed in this study. Following DNA extraction by boiling, the PAI 
IV536 gene fragment was amplified following standard procedure using the F5′-AAGGATTCGCTGTTACCGGAC-3′ and 
R5′-TCGTCGGGCAGCGTTTCTTCT-3′ primer pair. Of the 35 isolates, 13 were from clinical sources and 22 from non-
clinical sources. In total, 25.7% (9/35) of the E. coli isolates in this study were found to possess the PAI IV536 gene. 
Clinical isolates had a much higher association of 61.5% with the PAI IV536 gene than non-clinical which only had a 4.5% 
representation of the PAI IV536 gene. This study reports on the detection of PAI IV536 in E. coli isolates from Port Harcourt, 
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Escherichia coli is widely known as a commensal 
found in association with various human and non-
human systems particularly the gastrointestinal tract, 
where it exists without causing any observable harm 
(Allocati et al., 2013, Fratamico et al., 2016). These 
organisms exist as part of the normal flora of the 
intestines of humans but are routinely encountered in 
the environment due to faecal and wastewater 
discharges (Jang et al., 2017). E coli is however also 
notorious as a pathogen, notable as the most common 
human Gram-negative bacterial pathogen isolated in 
the clinical microbiology laboratory (Poolman and 
Wacker 2016, Vila et al., 2016). It is notorious for 
mediating a wide variety of infectious diseases ranging 
from mild self-limiting to more serious life-
threatening conditions. It is a leading cause of urinary 
tract infections, diarrheal diseases, bacteremia and 
meningitis (Vila et al., 2016, Poolman and Wacker 
2016).Commensal and pathogenic E. coli differ in the 
presence of specialized pathogenic and virulence 
factors in the pathogenic strains. These factors are of a 
variety of types and include invasins, adhesins, toxins, 
iron-acquisition systems and type three secretion 
system (Mainil 2013). These pathogenic strains of E. 
coli commonly develop due to gene acquisition, which 
provides the acquiring organism with new traits and 
often a fitness advantage. The genome sizes of the 
pathogenic variants have been found to differ by up to 
a million base pairs (Croxen et al., 2013), with an up 
to 20% variation found to occur between commensal 
and pathogen genomes (Ochman and Jones 2000). 
These extra genes which confer the pathogenic 
potential belong to a subset of genes referred to as the 
flexible gene pool. Gain or loss of such genes occurs 
at specific hotspots distributed all over the genome 
(Touchon et al., 2009). Some of these virulence genes 
may be encoded in chromosomal pathogenicity islands 
(Chekabab et al., 2013), which are a unique class of 
genomic islands. And these genomic islands have been 
found to be significant in defining E. coli (van Elsas et 
al., 2011). Two studies have noted that a quarter of the 
genomic content of particular pathogenic strains was 
made up of genomic islands (Chaudhuri et al., 2010, 
Perna et al., 2001). Pathogenicity islands (PAIs) are 
distinct chromosomal mobile genetic elements, 
obtained by horizontal gene transfer which contribute 
to genome evolution (Oelschalaeger and Hacker 
2004). These elements first described in E. coli 
(Schmidt and Hensel 2004) are known to carry 
virulence genes and, in some cases, antibiotic 
resistance genes. They are generally present in 
pathogenic strains but absent in non-pathogenic strains 
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(Gal-Mor and Finlay 2006). PAIs are generally 
associated with specific sites of the chromosome and 
mobility genes and elements. Characteristically, they 
have a G+C content which varies from the surrounding 
core genome. Several PAIs exist with up to 8 described 
(Calhau et al., 2015). One of such PAIs is the PAI 
IV536 initially associated with uropathogenic E. coli 
strain 536. PAI IV536 is a high pathogenicity island 
notable for its association with yersiniabactin, a 
siderophore system (Karczmarczyk et al., 2011). This 
particular pathogenicity island has been found 
associated with intestinal pathogens, uropathogens, 
extraintestinal pathogens and even commensals and is 
often the most commonly detected PAI in 
enterobacteria (Karczmarczyk et al., 2011, Dobrindt et 
al., 2002, Sabate et al., 2006, Koga et al., 2014). 
 
Quite often, potentially pathogenic species have been 
found in non-clinical settings such as poultry 
environments, ready-to-eat foods, drinking water 
systems and inanimate surfaces (Otokunefor et al., 
2018, Cookey and Otokunefor 2016, Agbagwa and 
Onyebule 2018). Often, they are found in association 
with high decrees of drug resistance. And concern has 
been expressed regarding the transfer of these isolates 
into the clinical settings and the potential human 
impact. Few studies have however set out to ascertain 
the actual pathogenic ability of isolates obtained. This 
study was therefore aimed at exploring the pathogenic 
ability of a panel of E. coli isolates based on the 
presence of a PAI IV536 marker. 
 
MATERIALS AND METHODS 
Bacterial Isolates: Thirty-five E. coli isolates were 
analyzed in this study. These isolates were obtained 
from the culture collection of the Bacteriology group 
of the Medical Microbiology Unit of the University of 
Port Harcourt. 
 
DNA extraction: The boiling method (Oliveira et al., 
2014) was used for DNA extraction in this study. Pure 
bacterial colonies were boiled in 100µL of molecular 
grade water for 5 min and impurities removed by 
centrifugation at 10,000g for 5min. Bacterial DNA 
contained in the supernatant was then used in the 
molecular studies. 
 
Detection of PAI marker: The PAI IV536 gene 
fragment was detected using previously described 
primers (Koga et al., 2014). Each amplification 
reaction mix comprised of 2µl master mix (5x), 0.3µl 
each of forward and reverse primer (10 pmol/µl), 2µl 
of DNA template and 5.4µl of H2O in a final volume 
of 10µl. The amplification protocol involved an initial 
denaturation at 95°C for 5 mins followed by 35 cycles 
of denaturation at 95°C for 1 min, annealing at 56°C 
for 30 secs and extension at 72°C for 2 min. it ended 
with a final extension of 72°C for 10 mins. Following 
amplification, PCR products were visualized on 1.5% 
agarose gels stained with ethidium bromide. 
 
RESULTS AND DISCUSSION 
Source of Isolates: Identities of the 35 E. coli isolates 
had previously been confirmed using both phenotypic 
and molecular methods (Otokunefor et al., 2019). Of 
these 35 isolates, 13 had been obtained from clinical 
sources and 22 from non-clinical sources. 
 
Detection of PAI IV536 gene: In total, 25.7% (9/35) of 
the E. coli isolates in this study were found to possess 
the PAI IV536 gene. The rate of carriage of this gene 
was however found to differ based on source of the 
isolates. Clinical isolates were found to exhibit a 
higher carriage rate than non-clinical isolates (Figure 
1), with a 57% difference in level of carriage. 
 
Fig 1: Presence of the pathogenicity island PAI IV536 gene marker 
in E. coli isolate 
 
Eight pathogenicity islands have commonly been 
described in E. coli isolates. One of the more 
commonly occurring of these pathogenicity islands is 
PAI IV536. Several studies exploring the prevalence of 
this island in various E. coli isolates have noted much 
higher rates (68% to 98.6%) than reported in this study 
(Sabate et al., 2006, Najafi et al., 2018, Samei et al., 
2016, Calhau et al., 2015, Kryger et al., 2015). In 
contrast, other studies reported lower rates similar to 
that obtained in this study ranging from 21% to 43% 
(Sabate et al., 2006, da Silva et al., 2017, Peerayeh et 
al., 2018). This variation appears to be linked in some 
cases to the source of isolates. The studies reporting 
high rates predominantly explored the rate of PAI 
IV536 in uropathogenic E. coli (UPEC) isolates, while 
the lower rates were described in enteroinvasive E. 
coli (EIEC) and commensals. The low association 
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between PAI IV536 and the non-clinical isolates 
analyzed in this study is a welcomed finding as it could 
point at a lower ability of these isolates to cause 
disease in humans hence indicating a reduced risk 
from these isolates if transferred into clinical settings. 
 
Conclusion: This study reports on the detection of 
PAI IV536 in E. coli isolates from Port Harcourt, 
Rivers State Nigeria. The lower association of this 
pathogenicity marker with non-clinical isolates is a 
welcomed finding. A larger scale study would be 
ideal to properly confirm the findings of this study. 
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